DexCom Shares Up 4% After FDA Approval of Continuous Glucose Monitoring System
December 08 2022 - 1:44PM
Dow Jones News
By Kathryn Hardison
Shares of DexCom Inc. increased 4.3% to $122.99 on Thursday
following clearance from the Food and Drug Administration for its
next-generation continuous glucose monitoring system.
The shares reached an intraday high of $125.55, a level last
seen April 21 when they traded at $125.95, according to FactSet.
The shares are 8.4% lower for the year.
DexCom said the FDA cleared its G7 continuous glucose monitoring
system for people aged two years and older with all types of
diabetes. The system is wearable and doesn't require fingersticks
or scanning, the company said.
Chief Executive Kevin Sayer said the system will become
commercially available in the coming months.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
December 08, 2022 13:29 ET (18:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024